Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
about
Tamoxifen Resistance: Emerging Molecular TargetsThe Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of JanusDrugging the undruggables: exploring the ubiquitin system for drug developmentMechanisms of oestrogen receptor (ER) gene regulation in breast cancerA Role for Notch Signalling in Breast Cancer and Endocrine ResistanceRevealing the Complexity of Breast Cancer by Next Generation SequencingOptimal management of hormone receptor positive metastatic breast cancer in 2016Roles for miRNAs in endocrine resistance in breast cancerNew and emerging factors in tumorigenesis: an overviewMechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNABreast cancer in 2013: Genomics, drug approval, and optimal treatment durationClinical tumor sequencing: opportunities and challenges for precision cancer medicineCIViC databaseCausal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving SurgeryRecent developments and translational aspects in targeted therapy for metastatic breast cancerAre Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?Antiestrogens: structure-activity relationships and use in breast cancer treatmentCurrent Status of Long Non-Coding RNAs in Human Breast CancerPatient-derived tumour xenografts for breast cancer drug discoveryHow sleep and wakefulness influence circadian rhythmicity: effects of insufficient and mistimed sleep on the animal and human transcriptomeIntegrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancerDeciphering the divergent roles of progestogens in breast cancer.A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.Exploiting human and mouse transcriptomic data: Identification of circadian genes and pathways influencing health.Data on affected cancer-related genes in pediatric t(12;21)-positive acute lymphoblastic leukemia patients harboring unbalanced der(6)t(X;6) translocations.Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancerMutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.FAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis.Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsDetecting independent and recurrent copy number aberrations using interval graphs.Precision medicine in breast cancer: reality or utopia?Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrationsVAV3 mediates resistance to breast cancer endocrine therapy.Molecular genetics complexity impeding research progress in breast and ovarian cancers.ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signalingPictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
P2860
Q26739969-0EF3070D-632C-4BEC-85AD-B8777E659B0BQ26740184-6E9A102C-5373-456E-963F-348E580537D8Q26752823-E0C751D6-92FD-4CD2-B771-A11424CBF2E4Q26765380-5B7BD051-3A9C-41C9-8BCC-87738595CABBQ26765912-375FEAA1-C583-4F2F-98BC-9D9F120BBF60Q26777395-B02952FE-5217-4669-B438-B57853F28626Q26777683-716D019A-484D-4F54-998D-FD33D7BE3345Q26783076-A7932302-F1FB-4CE0-AC7F-475C829A222BQ26801253-B9E1C6C3-D7CA-4C2C-AC87-B45955B1E386Q27011221-E4C7327B-0496-4717-ABEB-9B220D8A2168Q27021514-7B8931A3-0091-460C-B2C7-CE7775FB266EQ27027942-BEEF6DDC-607A-4B5B-B74E-CF48A3661997Q27612411-8FD221FA-4ACF-4889-8B0B-904124F6320FQ28069804-8C4C120D-770A-4583-933A-D118266BF82FQ28072755-9F21CB71-7ACA-44D7-9BD1-7AD65A501A57Q28074060-C5F7F178-0252-49DF-9FC8-2E82E8D890C3Q28077245-457F2B48-A968-4B88-A5DE-EE06FD3D10A5Q28079880-A370395D-F3EA-4ED4-8585-0DA3DE52CFC8Q28080046-ABBB96C0-391D-4401-BD06-14A64897C91DQ28081994-5A622F15-3575-4ABD-B7FC-3B7C9910D1D6Q28816965-7BACA42D-1078-4BB2-B718-27C4329AEE24Q30240711-540771AB-DB50-4E36-95D8-3E834353ADE8Q30355029-26E5C902-A26E-40AE-86EA-4F18EE05D959Q30910326-4AFE0782-81D8-45CA-81AF-E0C89DBDC0C1Q31120836-C2E1B443-5468-4FEB-8D1E-EE7A6E9C627EQ33585930-B43A7A4D-B705-491E-91E8-E071054DBCC1Q33618285-4085038A-8E92-4DEF-8601-AC47FAB327FEQ33629325-468D88B4-8F8B-4966-9FE6-F7D00CF4F7A9Q33641010-FB5257B3-C5DE-4D2B-B3F3-3CEFEDDCBBBFQ33656026-60FBD8B7-85F7-41B5-B42E-F232C27543E6Q33703311-DAE4DA76-262C-4B6C-A07E-464114DDA3C9Q33722765-B73844DD-6139-4927-BE2D-3CFBBEFA897DQ33756991-7DCAA8B3-9355-4D36-8619-364ADF6BF17FQ33760431-34BA2CBE-0F87-4F4F-9717-C876176E6D92Q33809114-64CF2C55-B2EF-479D-B266-5E6AE4E64B31Q33810500-04409C78-C5FD-46EC-AD51-65119BC84CEEQ33827037-28627F45-4F7E-4248-AA71-7D569067F9D4Q33858073-28C41BD4-D754-478B-B217-94C2AC35186BQ33903949-96EEABB5-739A-4856-9BFE-0CCD741373BBQ33925164-3B6723D7-53DE-4CF9-9BDF-6A28D0F0762C
P2860
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
@ast
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
@en
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
@nl
type
label
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
@ast
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
@en
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
@nl
altLabel
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
@en
prefLabel
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
@ast
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
@en
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
@nl
P2093
P2860
P3181
P356
P1433
P1476
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
@en
P2093
Amy Gursky
Anne F Schott
Arul M Chinnaiyan
Catherine H Van Poznak
Dan R Robinson
Daniel F Hayes
Fengyun Su
J Scott Roberts
James M Rae
Javed Siddiqui
P2860
P2888
P304
P3181
P356
10.1038/NG.2823
P407
P577
2013-12-01T00:00:00Z
P6179
1010741940